Sandoz Group AG

Company Snapshot

Founded: 1886
Entity Type: Public
Employees: 22,049
Region: Europe
Revenue: $10,357.0 Millions
Revenue Year: 2024
Headquarter: Basel, Switzerland
Key Geographics: North America, Europe, International

Company Overview

Sandoz operates in three business segments: retail generics, biopharmaceuticals, and anti-infectives. Retail Generics include finished dosage forms of small-molecule pharmaceuticals. Sandoz offers protein- and other biotechnology-based products in Biopharmaceuticals, including biosimilars and biotechnology manufacturing services to other companies. In Anti-Infectives, Sandoz manufactures and supplies APIs and intermediates. The company offers over 1,500 products to nearly 500 million patients in more than 100 countries. In October 2023, Sandoz became a standalone company after separation from Novartis. The company shifted its headquarters to Basel, Switzerland.

Financial Highlights (FY 2023)

Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***

This information is available for BCC Research members only.

Sandoz Group AG In Reports

Biosimilars: Global Markets

BCC Research Report: Dive into biosimilars market estimates, data has been provided for 2021 and 2022 as the historic years, 2023 as the base year, and forecast for 2029.

Global Recombinant Proteins Market

BCC Research Market Analyst says global market for recombinant proteins is estimated to increase from $132.4 billion in 2023 to reach $203.6 billion by 2029, at a CAGR of 7.5%.

PEGylated Proteins Market

BCC Research Market Analyst says global market for PEGylated proteins is expected to grow from $10.2 billion in 2023 and projected to reach $15.9 billion by the end of 2028, at a CAGR of 9.4%.

Applications/End User Industries

  • Healthcare
  • Pharmaceuticals